^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Apoptosis inhibitor

2d
Targeting Mycobacterium tuberculosis GAPDH elicits potent bactericidal responses by dysregulating enzyme activity, redox dynamics and iron acquisition. (PubMed, Free Radic Biol Med)
Overall, this study identifies the crucial function of Mtb GAPDH as a redox sensor and highlights the potential of targeting its pleiotropic cellular functions towards drug discovery. In addition, the efficacy of TCH346 provides an opportunity of drug-repurposing as a strategy for therapy.
Journal
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
2d
New P2 trial
3d
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Bifidobacterium Tetravaccine Live Tablets in the Treatment of Patients with Cholestatic Liver Disease (ChiCTR2500112906)
P=N/A, N=198, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
New trial
3d
Efficacy and Safety of Ursodeoxycholic Acid in Participants with Mild to Moderate Ulcerative Colitis: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR2500113946)
P3, N=378, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
New P3 trial
25d
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (clinicaltrials.gov)
P3, N=150, Recruiting, Xijing Hospital of Digestive Diseases | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
26d
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis (clinicaltrials.gov)
P2/3, N=104, Recruiting, Xijing Hospital of Digestive Diseases | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
26d
Effect of Bupleuri Radix-Paeoniae Radix Albae combination on HMGB1/RAGE/NF-κB signaling pathway in rats with cholestatic hepatitis (PubMed, Zhongguo Zhong Yao Za Zhi)
To explore the effect of the combination of Bupleuri Radix and Paeoniae Radix Alba on the high mobility group box-1 protein(HMGB1)/receptor for advanced glycation end-products(RAGE)/nuclear factor-κB(NF-κB) signaling pathway in rats with cholestatic hepatitis induced by rifampicin(RFP). Forty-two male SD rats were randomly divided into the normal group, the Bupleuri Radix-Paeoniae Radix Alba group(C-B group), the RFP group, the ursodeoxycholic acid(UDCA)+RFP group(UDCA+RFP group), the Bupleuri Radix+RFP group(C+RFP group), the Paeoniae Radix Alba+RFP group(B+RFP group), and the Bupleuri Radix-Paeoniae Radix Alba+RFP group(C-B+RFP group)...Compared with the C-B+RFP group, the ALT activity and the protein expression levels of HMGB1, RAGE, IL-6, and GRP78 were significantly higher in the C+RFP and the B+RFP groups. In conclusion, the combination of Bupleuri Radix and Paeoniae Radix Alba alleviates endoplasmic reticulum stress through the HMGB1/RAGE/NF-κB signaling pathway and reduces inflammatory responses, thereby exerting hepatoprotective effects.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • IL1B (Interleukin 1, beta)
|
rifampicin
1m
Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy (clinicaltrials.gov)
P=N/A, N=90, Completed, Institute of Liver and Biliary Sciences, India | Not yet recruiting --> Completed
Trial completion
2ms
Multi-organ protective effects of ursodeoxycholic acid in a rat model of type 2 diabetes mellitus. (PubMed, Biochem Biophys Res Commun)
Concurrently, UDCA significantly suppressed the secretion of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP), mitigated oxidative stress, and inhibited β-cell apoptosis by modulating the expression of Bcl-2 and Bax genes. Collectively, these results indicate that UDCA exerts substantial therapeutic potential in ameliorating metabolic disturbances, repairing organ damage, and regulating critical signaling pathways via multi-target synergistic actions, thereby providing novel experimental evidence supporting its pharmacological application in the treatment of T2DM and its associated complications.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • PDX1 (Pancreatic And Duodenal Homeobox 1) • CRP (C-reactive protein)
2ms
Bacterial extracellular vesicle ssRNA prevents colorectal cancer progression via Piezo1. (PubMed, Cell Rep)
In the present study, we demonstrate that ssRNA within fecal extracellular vesicles (FEVs) derived from bacteria, particularly those susceptible to lysis by ursodeoxycholic acid (UDCA), can suppress CRC progression via Piezo1 activation...Notably, oral UDCA administration enhanced FEV rupture, increasing luminal "naked" ssRNA and mitigating high-fat diet-induced CRC in vivo. These findings identify the bacterial ssRNA-Piezo1 axis as a potential therapeutic target in CRC.
Journal
|
LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
2ms
THEUDCA: UDCA to Prevent Post-TIPS Hepatic Encephalopathy (clinicaltrials.gov)
P=N/A, N=270, Not yet recruiting, West China Hospital
New trial
2ms
Tumor necrosis factor alpha-induced protein 3: Biomarker discovery and therapeutic advancement in primary biliary cholangitis. (PubMed, World J Hepatol)
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) was examined in this study as a novel biomarker to predict the efficiency of ursodeoxycholic acid (UDCA) and thereby improved primary biliary cholangitis (PBC) treatment...In conclusion, TNFAIP3 and fatigue have significant impact on UDCA in PBC. These findings provide a new view on PBC pathophysiology and suggest that TNFAIP3 may be a suitable biomarker or therapeutic target for the disease.
Journal
|
TNFAIP3 (TNF Alpha Induced Protein 3)